TL;DR
This study reveals a strong link between Epithelial-to-Mesenchymal Transition (EMT) and fibrosis in clear cell renal cell carcinoma (ccRCC), a deadly kidney cancer. The researchers found that EMT markers are elevated in ccRCC, and this transition is associated with fibrosis and worse patient survival, suggesting new therapeutic targets.
What Problem Does This Paper Address?
Clear cell renal cell carcinoma (ccRCC) is a significant cause of kidney cancer mortality, especially in advanced stages. While the epithelial-to-mesenchymal transition (EMT) is known to drive cancer progression, invasiveness, and metastasis in various cancers, its specific role and prognostic implications in ccRCC, particularly in relation to fibrosis, remained less understood. This paper aims to bridge this gap by investigating the correlation between EMT, fibrosis, and patient survival in ccRCC.
Methods
The researchers employed a multi-omics approach:
- RNA Sequencing (RNA-seq): They performed both mRNA and microRNA sequencing on renal biopsies from 26 ccRCC patients and their adjacent non-tumorous tissue. This allowed for a comprehensive analysis of gene and microRNA expression.
- Proteomics: Liquid chromatography-tandem mass spectrometry was used to measure protein abundance, providing a complementary layer of data to the RNA-seq findings.
- Immunohistochemistry (IHC): This technique was used to visualize the protein expression of key EMT markers (AXL, CDH1, MMP14, VIM) in tissue samples, confirming findings from RNA-seq and proteomics.
- EMT Score Calculation: A generic EMT score, based on the enrichment of a set of 315 EMT-related genes, was calculated to quantify the degree of EMT in samples.
- Bioinformatics Analysis: This included differential gene expression analysis (Limma/voom R-package), principal component analysis (PCA) for data structure exploration, and survival analysis using publicly available datasets (TCGA).
- Fibrosis Classifier Application: Previously developed MARGS-based fibrosis classifiers were applied to ccRCC samples to assess the presence of fibrosis and its correlation with patient survival.
Datasets
- Patient Cohort: Renal core biopsies from 26 ccRCC patients (10 females, 16 males) who underwent partial or radical nephrectomy at Haukeland University Hospital in Bergen, Norway. All patients had tumor-negative lymph nodes and no metastases.
- Publicly Available Datasets:
- TCGA ccRCC dataset (468 samples for mRNA analysis, 217 samples for microRNA analysis) was used for survival analysis.
- EMT gene lists were compiled from three publicly available sources: http://dbemt.bioinfo-minzhao.org/, Chen et al. (2014), and Groger et al. (2012).
- MARGS-based fibrosis classifiers developed by Rodder et al. (2009, 2011) were used.
Key Insights and Ideas
- EMT is a Hallmark of ccRCC: The study unequivocally demonstrates an increased EMT transcript score in ccRCC samples compared to adjacent normal tissue, suggesting EMT is a fundamental process in ccRCC development.
- EMT and Fibrosis are Intertwined: Several EMT-related genes identified in this study also play known roles in fibrosis. Furthermore, established fibrosis classifiers successfully identified EMT-affected tumor samples and correlated with patient survival. This highlights a critical link between EMT and fibrotic processes in ccRCC.
- Specific Genes as Prognostic Indicators: The study pinpoints specific genes like AXL and MMP14 as significantly associated with patient survival, with higher expression correlating with worse outcomes. Conversely, lower expression of KL (klotho) is linked to poorer survival.
- MicroRNA Regulation: The study shows a positive correlation between miR-34a and its targets MMP14 and AXL, suggesting a regulatory role for this microRNA in EMT. However, intriguingly, miR-34a itself did not show prognostic value in this ccRCC cohort, despite being highly expressed in high-risk groups.
- Gene Panels for Prognosis: Combinations of genes, particularly a panel of four collagen genes and a panel of eleven EMT-related genes, demonstrated superior predictive value for patient survival compared to individual genes.
Key Results
- Increased EMT Score: 25 out of 26 ccRCC sample pairs showed significantly higher EMT scores in tumor tissue compared to normal tissue.
- Differential Gene Expression: Augmented abundance of AXL and MMP14, and down-regulated expression of KL (klotho) were observed in ccRCC.
- Survival Correlation: Higher MMP14 and AXL mRNA levels were significantly associated with worse patient survival. Lower KL expression was also linked to poorer survival.
- Fibrosis Classifier Performance: MARGS-based fibrosis classifiers achieved 100% correct classification of ccRCC samples and were correlated with patient survival.
- Gene Panel Efficacy: A panel of four collagen genes showed a Risk Group Hazard Ratio of 3.19 (P = 1.11E-11), and a panel of eleven genes achieved a Hazard Ratio of 4.28 (P = 1.32E-15) for predicting patient survival.
Limitations and Future Work
- Sample Size: The study acknowledges a limitation in the sample size of kidney biopsies (n=26 for the primary cohort).
- Tumor Heterogeneity: The authors note that cellular heterogeneity within tumors and adjacent normal tissues can influence results, and their findings represent a summation of this variability.
- Cell-Specificity: The need for tissue microdissection or single-cell sequencing to address cell-specificity of gene expression is highlighted.
- Future Therapeutic Targets: The strong association of EMT and fibrosis with worse survival suggests that EMT-related genes, particularly those involved in fibrosis, represent promising targets for novel therapeutic interventions. The study specifically points to AXL inhibition as a potential therapeutic avenue, with ongoing clinical trials for related inhibitors. Further exploration of the role of CAV1 and ITGA5 in ccRCC is also warranted.
Summary updated